Carcinoembryonal Antigen Idiotype Vaccine
Small Business Information
300 American Road, Morris Plains, NJ, 07950
Hans J. Hansen
AbstractCancer patients are usually tolerant to the antigens expressed on tumor cells. Triggering an active immune response by the patients to tumor-associated antigens represents one of the most promising prospects in cancer therapy. In this project, we will perform a preclinical study of the anti-idiotype approach to trigger an active immune response against CEA. Certain anti-idiotypic antibodies directed against the variable regions of antibodies specific for a given antigen can mimic (i. e., bear the internal image of) this antigen. In several experimental systems, immunization with anti-idiotypic antibodies elicited specific immunity in lieu of the original antigen. Immunization with anti-idiotype antibodies as surrogate antigens is a promising approach to trigger immunity to tolerized antigens such as tumor antigens. They have already generated baboon polyclonal and rat monoclonal anti-idiotype antibodies that antigenically mimic CEA. In this project, they will assess whether these anti-idiotype antibodies can function as surrogate antigens in hamsters. Hamsters have been chosen since they are the only known non-immunodeficient animal species in which human CEA-producing tumors may grow. Hamsters represent a unique model to test whether active anti-idiotype immunization can protect against tumor growth. This Phase I study will represent the basis for more extensive preclinical and clinical studies in Phase II.
* information listed above is at the time of submission.